Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

2025 ARTÍCULOS , VIENDO DEL 1276 AL 1290

Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease

Salloway S, Wojtowicz J, Voyle N, Lane CA, Klein G, Lyons M, Rossomanno S, Mazzo F, Bullain S, Barkhof F, Bittner T, Schneider A, Grundman M, Aldea R, Boada M, Smith J, Doody R.

JAMA Neurol. 2025 Jan 1;82(1):19-29. doi: 10.1001/jamaneurol.2024.3937.

A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research

Iaccarino L, Burnham SC, Tunali I, Wang J, Navitsky M, Arora AK, Pontecorvo MJ.

Neuroimage Clin. 2025;46:103765. doi: 10.1016/j.nicl.2025.103765. Epub 2025 Mar 10.

Traditional Chinese Medicine for Alzheimer's Disease: A Systematic Review and Meta-Analysis

Chen Y, Zhang D, Chen T, Zhao L, Wen L, Hou R.

Am J Chin Med. 2025;53(1):1-15. doi: 10.1142/S0192415X25500016. Epub 2025 Feb 21.

Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms

Greenberg SM, Bax F, van Veluw SJ.

Nat Rev Neurol. 2025 Apr;21(4):193-203. doi: 10.1038/s41582-024-01053-8. Epub 2025 Jan 10.

Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial

Macfarlane S, Grimmer T, Teo K, O'Brien TJ, Woodward M, Grunfeld J, Mander A, Brodtmann A, Brew BJ, Morris P, Short C, Kurrle S, Lai R, Bharadwaj S, Drysdale P, Sturm J, Lewis SJG, Barton D, Kalafatis C, Sharif S, Perry R, Mannering N, MacSweeney JE, Pearson S, Evans C, Krishna V, Thompson A, Munisamy M, Bhatt N, Asher A, Connell S, Lynch J, Rutgers SM, Dautzenberg PL, Prins N, Oschmann P, Frölich L, Tacik P, Peters O, Wiltfang J, Henri-Bhargava A, Smith E, Pasternak S, Frank A, Chertkow H, Ingram J, Hsiung GR, Brittain R, Tartaglia C, Cohen S, Villa LM, Gordon E, Jubault T, Guizard N, Tucker A, Kaufmann WE, Jin K, Chezem WR, Missling CU, Sabbagh MN.

J Prev Alzheimers Dis. 2025 Jan;12(1):100016. doi: 10.1016/j.tjpad.2024.100016. Epub 2025 Jan 1.

Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities

Cogswell PM, Andrews TJ, Barakos JA, Barkhof F, Bash S, Benayoun MD, Chiang GC, Franceschi AM, Jack CR Jr, Pillai JJ, Poussaint TY, Raji CA, Ramanan VK, Tanabe J, Tanenbaum L, Whitlow CT, Yu FF, Zaharchuk G, Zeinah M, Benzinger TS; ASNR Alzheimer, ARIA, and Dementia Study Group.

AJNR Am J Neuroradiol. 2025 Jan 8;46(1):24-32. doi: 10.3174/ajnr.A8469.

Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup

Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, Herscovitch P, Kuo PH, Lingler JH, Minoshima S, Murray ME, Price JC, Salloway SP, Weber CJ, Carrillo MC, Johnson KA.

Alzheimers Dement. 2025 Jan;21(1):e14338. doi: 10.1002/alz.14338. Epub 2025 Jan 8.

Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy

Wolk DA, Nelson PT, Apostolova L, Arfanakis K, Boyle PA, Carlsson CM, Corriveau-Lecavalier N, Dacks P, Dickerson BC, Domoto-Reilly K, Dugger BN, Edelmayer R, Fardo DW, Grothe MJ, Hohman TJ, Irwin DJ, Jicha GA, Jones DT, Kawas CH, Lee EB, Lincoln K, Maestre GE, Mormino EC, Onyike CU, Petersen RC, Rabinovici GD, Rademakers R, Raman R, Rascovsky K, Rissman RA, Rogalski E, Scheltens P, Sperling RA, Yang HS, Yu L, Zetterberg H, Schneider JA.

Alzheimers Dement. 2025 Jan;21(1):e14202. doi: 10.1002/alz.14202. Epub 2025 Jan 14.

Alzheimer's disease: insights into pathology, molecular mechanisms, and therapy

Zheng Q, Wang X.

Protein Cell. 2025 Feb 1;16(2):83-120. doi: 10.1093/procel/pwae026.

A multifactorial lens on risk factors promoting the progression of Alzheimer's disease

Parker J, Moris JM, Goodman LC, Paidisetty VK, Vanegas V, Turner HA, Melgar D, Koh Y.

Brain Res. 2025 Jan 1;1846:149262. doi: 10.1016/j.brainres.2024.149262. Epub 2024 Oct 5.

Impact of Mouthwash-Induced Oral Microbiome Disruption on Alzheimer's Disease Risk: A Perspective Review

Boulares A, Jdidi H, Bragazzi NL.

Int Dent J. 2025 Feb;75(1):45-50. doi: 10.1016/j.identj.2024.07.005. Epub 2024 Oct 8.

The Role of Genetic, Environmental, and Dietary Factors in Alzheimer's Disease: A Narrative Review

Mertaş B, Boşgelmez Iİ.

Int J Mol Sci. 2025 Jan 30;26(3):1222. doi: 10.3390/ijms26031222.

The effect of anti-seizure medications on Alzheimer's disease (AD) risk and AD-related symptoms: A scoping review

Williams JP, Zhu Y, Singh RK, Beyene K, Rani R, Kapetanakos X, Dias A, McGuire K, Kolady R, Lipsey K, Ramaswamy SG, Thotakura V, Trani JF, Babulal GM.

J Alzheimers Dis. 2025 May;105(1):3-14. doi: 10.1177/13872877251324663. Epub 2025 Mar 21.

Exploring the connection between dementia and cardiovascular risk with a focus on ADAM10

Targas ABA, Victoriano PHM, Garcia MBB, Alexandre-Silva V, Cominetti MR.

Biochim Biophys Acta Mol Basis Dis. 2025 Jun;1871(5):167825. doi: 10.1016/j.bbadis.2025.167825. Epub 2025 Mar 31.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias